And the increased expression of inhibitory receptors was a key feature of this phenomenon, consistent with the increased expression of TIGIT on CD4+ T cells of HBV-HCC patients in our study, this provides a potential rationale for developing therapeutic modalities targeting TIGIT to prevent HCC progression and promote survival. Here, TIGIT is linked to hepatocellular carcinoma.